These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37807783)

  • 1. Informing Disclosure: Efficacy of a Brief Educational Intervention on Research Participants' Knowledge about Alzheimer's Disease Biomarkers.
    Ketchum FB; Erickson CM; Basche KE; Chin NA; Rosario HL; Johnson SC; Clark LR
    J Alzheimers Dis; 2023; 96(2):515-522. PubMed ID: 37807783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Family members' perspectives on learning cognitively unimpaired older adults' amyloid-β PET scan results.
    Largent EA; Abera M; Harkins K; Feldman SJ; Uhlmann WR; Roberts JS; Karlawish J;
    J Am Geriatr Soc; 2021 Nov; 69(11):3203-3211. PubMed ID: 34252201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spillover: The Approval of New Medications for Alzheimer's Disease Dementia Will Impact Biomarker Disclosure Among Asymptomatic Research Participants.
    Mozersky J; Roberts JS; Rumbaugh M; Chhatwal J; Wijsman E; Galasko D; Blacker D;
    J Alzheimers Dis; 2022; 90(3):1035-1043. PubMed ID: 35404285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results.
    Largent EA; Harkins K; van Dyck CH; Hachey S; Sankar P; Karlawish J
    PLoS One; 2020; 15(2):e0229137. PubMed ID: 32053667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evolution of the diagnostic frontiers of Alzheimer's disease and new therapeutic possibilities].
    Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(11. Vyp. 2):38-44. PubMed ID: 36412155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes.
    Long JM; Coble DW; Xiong C; Schindler SE; Perrin RJ; Gordon BA; Benzinger TLS; Grant E; Fagan AM; Harari O; Cruchaga C; Holtzman DM; Morris JC
    Brain; 2022 Dec; 145(12):4506-4518. PubMed ID: 35867858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials.
    Grill JD; Zhou Y; Elashoff D; Karlawish J
    Neurobiol Aging; 2016 Mar; 39():147-53. PubMed ID: 26923411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
    Rafii MS; Sperling RA; Donohue MC; Zhou J; Roberts C; Irizarry MC; Dhadda S; Sethuraman G; Kramer LD; Swanson CJ; Li D; Krause S; Rissman RA; Walter S; Raman R; Johnson KA; Aisen PS
    Alzheimers Dement; 2023 Apr; 19(4):1227-1233. PubMed ID: 35971310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-disclosure distress among racial and ethnic groups in a preclinical AD trial.
    Ritchie M; Salazar CR; Gillen DL; Grill JD
    Alzheimers Dement; 2024 Apr; 20(4):2508-2515. PubMed ID: 38329007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
    Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing.
    Ketchum FB; Chin NA; Grill J; Gleason CE; Erickson C; Clark LR; Paulsen JS; Kind AJH
    Alzheimers Dement; 2022 Oct; 18(10):1969-1979. PubMed ID: 35213786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease.
    Grau-Rivera O; Navalpotro-Gomez I; Sánchez-Benavides G; Suárez-Calvet M; Milà-Alomà M; Arenaza-Urquijo EM; Salvadó G; Sala-Vila A; Shekari M; González-de-Echávarri JM; Minguillón C; Niñerola-Baizán A; Perissinotti A; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Gispert JD; Molinuevo JL;
    Alzheimers Res Ther; 2021 Feb; 13(1):46. PubMed ID: 33597012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives From Black and White Participants and Care Partners on Return of Amyloid and Tau PET Imaging and Other Research Results.
    Rahman-Filipiak A; Lesniak M; Sadaghiyani S; Roberts S; Lichtenberg P; Hampstead BM
    Alzheimer Dis Assoc Disord; 2023 Oct-Dec 01; 37(4):274-281. PubMed ID: 37890053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Communicating Alzheimer's biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudes.
    Erickson CM; Ketchum FB; Basche KE; Chin NA; Eveler ML; Clark LR
    Alzheimers Dement (N Y); 2024; 10(2):e12483. PubMed ID: 38882702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer's disease polygenic risk score.
    Tomassen J; den Braber A; van der Lee SJ; Reus LM; Konijnenberg E; Carter SF; Yaqub M; van Berckel BNM; Collij LE; Boomsma DI; de Geus EJC; Scheltens P; Herholz K; Tijms BM; Visser PJ
    BMC Neurol; 2022 Dec; 22(1):484. PubMed ID: 36522743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.
    Jansen WJ; Janssen O; Tijms BM; Vos SJB; Ossenkoppele R; Visser PJ; ; Aarsland D; Alcolea D; Altomare D; von Arnim C; Baiardi S; Baldeiras I; Barthel H; Bateman RJ; Van Berckel B; Binette AP; Blennow K; Boada M; Boecker H; Bottlaender M; den Braber A; Brooks DJ; Van Buchem MA; Camus V; Carill JM; Cerman J; Chen K; Chételat G; Chipi E; Cohen AD; Daniels A; Delarue M; Didic M; Drzezga A; Dubois B; Eckerström M; Ekblad LL; Engelborghs S; Epelbaum S; Fagan AM; Fan Y; Fladby T; Fleisher AS; Van der Flier WM; Förster S; Fortea J; Frederiksen KS; Freund-Levi Y; Frings L; Frisoni GB; Fröhlich L; Gabryelewicz T; Gertz HJ; Gill KD; Gkatzima O; Gómez-Tortosa E; Grimmer T; Guedj E; Habeck CG; Hampel H; Handels R; Hansson O; Hausner L; Hellwig S; Heneka MT; Herukka SK; Hildebrandt H; Hodges J; Hort J; Huang CC; Iriondo AJ; Itoh Y; Ivanoiu A; Jagust WJ; Jessen F; Johannsen P; Johnson KA; Kandimalla R; Kapaki EN; Kern S; Kilander L; Klimkowicz-Mrowiec A; Klunk WE; Koglin N; Kornhuber J; Kramberger MG; Kuo HC; Van Laere K; Landau SM; Landeau B; Lee DY; de Leon M; Leyton CE; Lin KJ; Lleó A; Löwenmark M; Madsen K; Maier W; Marcusson J; Marquié M; Martinez-Lage P; Maserejian N; Mattsson N; de Mendonça A; Meyer PT; Miller BL; Minatani S; Mintun MA; Mok VCT; Molinuevo JL; Morbelli SD; Morris JC; Mroczko B; Na DL; Newberg A; Nobili F; Nordberg A; Olde Rikkert MGM; de Oliveira CR; Olivieri P; Orellana A; Paraskevas G; Parchi P; Pardini M; Parnetti L; Peters O; Poirier J; Popp J; Prabhakar S; Rabinovici GD; Ramakers IH; Rami L; Reiman EM; Rinne JO; Rodrigue KM; Rodríguez-Rodriguez E; Roe CM; Rosa-Neto P; Rosen HJ; Rot U; Rowe CC; Rüther E; Ruiz A; Sabri O; Sakhardande J; Sánchez-Juan P; Sando SB; Santana I; Sarazin M; Scheltens P; Schröder J; Selnes P; Seo SW; Silva D; Skoog I; Snyder PJ; Soininen H; Sollberger M; Sperling RA; Spiru L; Stern Y; Stomrud E; Takeda A; Teichmann M; Teunissen CE; Thompson LI; Tomassen J; Tsolaki M; Vandenberghe R; Verbeek MM; Verhey FRJ; Villemagne V; Villeneuve S; Vogelgsang J; Waldemar G; Wallin A; Wallin ÅK; Wiltfang J; Wolk DA; Yen TC; Zboch M; Zetterberg H
    JAMA Neurol; 2022 Mar; 79(3):228-243. PubMed ID: 35099509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability.
    Lim YY; Maruff P; Getter C; Snyder PJ
    Alzheimers Dement; 2016 Apr; 12(4):454-8. PubMed ID: 26750717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials.
    Rahman-Filipiak A; Bolton C; Grill JD; Rostamzadeh A; Chin N; Heidebrink J; Getz S; Fowler NR; Rosen A; Lingler J; Wijsman E; Clark L;
    Alzheimers Dement; 2023 Sep; 19(9):4270-4275. PubMed ID: 37450489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher plasma β-synuclein indicates early synaptic degeneration in Alzheimer's disease.
    Oeckl P; Janelidze S; Halbgebauer S; Stomrud E; Palmqvist S; Otto M; Hansson O
    Alzheimers Dement; 2023 Nov; 19(11):5095-5102. PubMed ID: 37186338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.